CHGCF News and Press, Chugai Pharmaceutical

2026-03-04 10:07:05 ET More on Protara Therapeutics Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers Symposium - Slideshow Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - S...

2026-01-29 14:12:32 ET Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call January 29, 2026 3:30 AM EST... Read the full article on Seeking Alpha For further details see: Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call Transcript

2026-01-29 04:26:26 ET More on Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation Chugai Pharmaceutical Co., Ltd. (CHGCY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Seeking Alpha&#...

2026-01-08 07:20:06 ET More on Gilead Sciences, CVS , etc. Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow CVS Health Corporation (CVS) Analyst/Investor Day Prepared Remarks Transcript ...

2025-12-18 13:22:23 ET More on Eli Lilly, Intercontinental Exchange Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) Eli Lilly: The Right Long-Term Strategy Eli Lilly Further Cements Itself As The King Of Weight Loss Medicare-negotiated drug prices t...

2025-12-13 04:33:24 ET Introduction Eli Lilly ( LLY ) has generated their Keytruda/Humira moment. A generation-defining medicine that in fact owns a duopoly, for the time being, with Novo Nordisk ( NVO ). Cash flows for the next few years will be immense but will become ...

2025-11-27 07:20:44 ET Introduction As the year comes to an end, we must be thankful for the therapies that are in late clinical stages. Most importantly, patients are set to benefit immensely. But nearly every trial candidate has implications beyond just patients. The approval of a...

2025-11-05 15:22:53 ET ... Read the full article on Seeking Alpha For further details see: Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks

2025-10-30 00:30:00 ET The following segment was excerpted from the Harding Loevner International Equity ADR Q3 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Harding Loevner International Equity ADR Q3 2025 Portfolio Update

2025-10-17 09:56:27 ET More on Rani Therapeutics, Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. 2025 Q2 - Results - Earnings Call Presentation Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2025 Earnings Call Transcript Rani Therapeutics secures $60.3M ...